RESUMO
OBJECTIVES: We aimed to retrospectively evaluate retention rate and causes of discontinuation of JAKi in rheumatoid arthritis (RA) patients with particular regards to difficult-to-treat subgroups. METHODS: The diffusion of Janus kinase inhibitors (JAKi) for the treatment of RA has rapidly increased in recent years due to their effectiveness, even in difficult-to-treat subgroups of patients. After the publication of the Oral Surveillance study, the labelling of JAKi was modified, advising against their use in elderly patients and those at risk for cardiovascular events and malignancies. Demographic, clinical, serological and therapeutic characteristics of RA patients treated with JAKi were recorded, including smoking habit and comorbidities. RESULTS: Three hundred and thirty consecutive RA patients were enrolled in the study. Among them, 50.3% patients had previously failed at least two biologic DMARDs. Risk factors for the use of JAKi were reported in 75.5% of patients, 41.5% of them were older than 65 years, 37.6% had smoked, while 48.8% had increased cardiovascular or cancer risk. Anticitrullinated peptide antibodies (ACPA) and combination therapy with conventional synthetic DMARDs were associated with a longer drug persistence and ACPA remained independently associated to a higher retention rate of JAKi also in the subgroup of difficult-to-treat patients. CONCLUSIONS: In conclusion, our study supports the clinical effectiveness of JAKi in RA, even in the multi-failure subgroup of patients, where the risk/benefit ratio overcomes the safety risk. The presence of ACPA and the concurrent use of + cs-DMARD may increase the survival on JAKi in the long term.
Assuntos
Antirreumáticos , Artrite Reumatoide , Inibidores de Janus Quinases , Humanos , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/diagnóstico , Masculino , Inibidores de Janus Quinases/uso terapêutico , Inibidores de Janus Quinases/efeitos adversos , Feminino , Idoso , Pessoa de Meia-Idade , Estudos Retrospectivos , Antirreumáticos/uso terapêutico , Antirreumáticos/efeitos adversos , Fatores de Risco , Fatores de Tempo , Falha de Tratamento , Quimioterapia Combinada , Anticorpos Antiproteína Citrulinada/sangueRESUMO
Para avaliação da atividade antimicrobiana de Ilex paraguariensis foram utilizados seis microrganismos: Candida albicans, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus e Staphylococcus epidermidis. O método utilizado foi de difusão do disco. Foram adicionados em discos de papel filtro 10 µl de extratos hidro-alcoólicos das folhas e ramos coletados de dois ambientes distintos, com e sem exposição ao sol. As placas foram incubadas a 35- 37 ºC por 24 h. Os extratos inibiram levedura, bacilos gram-negativos e cocos gram-positivos, não mostrando atividade frente à Escherichia coli.
For the evaluation of the antimicrobial activity of Ilex paraguariensis six microorganisms were used: Candida albicans, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis. In disks of filter paper 10 µl of hydro-alcoholic extracts of the leaves and branches from two distinct environments were added, with and without sun exposure. The extracts have inhibited levedura, gram-negative bacillus and gram-positive cocos, with no activity to Escherichia coli.